BindingDB logo
myBDB logout

66 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
10206553 55 Combined NK1 and NK2 tachykinin receptor antagonists: synthesis and structure-activity relationships of novel oxazolidine analogues.EBI Sankyo Co., Ltd.
28105278 10 Hydrazone Linker as a Useful Tool for Preparing Chimeric Peptide/Nonpeptide Bifunctional Compounds.EBI Mossakowski Medical Research Centre Polish Academy of Sciences
26048800 55 Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitors.EBI Bristol-Myers Squibb Co.
24075145 17 Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.EBI GlaxoSmithKline Medicines Research Centre
23899615 18 Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.EBI University of Arizona
23735006 17 Constrained H-Phe-Phe-NH2 analogues with high affinity to the substance P 1-7 binding site and with improved metabolic stability and cell permeability.EBI Uppsala University
12877589 2 Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.EBI Novartis Pharma AG
9046350 8 Conformational analysis of three NK1 tripeptide antagonists: a proton nuclear magnetic resonance study.EBI Universit£ degli Studi di Napoli Federico II
7678430 23 Cyclic peptides as selective tachykinin antagonists.EBI Merck Sharp and Dohme Research Laboratories
 6 Peptide azoles: A new class of biologically-active dipeptide mmetics.EBI TBA
21421318 25 Non-peptide NK1 receptor ligands based on the 4-phenylpyridine moiety.EBI Universit£ degli Studi di Siena
20560643 71 Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists.EBI University of Arizona
10543877 25 Design, synthesis, and evaluation of Phe-Gly mimetics: heterocyclic building blocks for pseudopeptides.EBI Uppsala University
9703462 98 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.EBI Novartis Institute for Medical Sciences
7518002 38 Studies on neurokinin antagonists. 4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists: N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N- methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and its related compounds.EBI Fujisawa Pharmaceutical Co., Ltd.
7515443 79 Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 receptor.EBI Universit£ P. et M. Curie
7693945 6 Synthesis, in vitro binding profile, and autoradiographic analysis of [3H]-cis-3-[(2-methoxybenzyl)amino]-2-phenylpiperidine, a highly potent and selective nonpeptide substance P receptor antagonist radioligand.EBI Pfizer Central Research
8388471 28 Tetrapeptide tachykinin antagonists: synthesis and modulation of the physicochemical and pharmacological properties of a new series of partially cyclic analogs.EBI Institut de Recherches Servier
1331460 54 Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2 receptor agonists.EBI Glaxo Group Research
1370695 27 Synthesis and substance P receptor binding activity of androstano[3,2-b]pyrimido[1,2-a]benzimidazoles.EBI Rochester
1375965 47 Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenylalanine sequence as substance P antagonists.EBI Fujisawa Pharmaceutical Co., Ltd.
1851847 22 Imidazo[4,5-b]quinoxaline cyanines as neurokinin antagonists.EBI Rochester
2441057 22 Binary drugs: conjugates of purines and a peptide that bind to both adenosine and substance P receptors.EBI TBA
12127519 40 Identification of a novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-(methoxyimino)pentyl]-2-oxo-(1,4'-bipiperidine) as a dual NK(1)/NK(2) antagonist.EBI The Schering Plough Research Institute
11266174 51 Design of non-peptide CCK2 and NK1 peptidomimetics using 1-(2-nitrophenyl)thiosemicarbazide as a novel common scaffold.EBI Novartis Institute for Medical Sciences
9873386 15 Synthesis and NK1 receptor antagonistic activity of (+/-)-1-acyl-3-(3,4- dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines.EBI Yamanouchi Pharmaceutical Co., Ltd.
 52 Synthesis and sar of 4-(1H-benzimidazole-2-carbonyl)piperidines with dual histamine H1/tachykinin NK1 receptor antagonist activityEBI TBA
 31 An SAR study for the non-peptide substance P receptor (NK1) antagonist, CP-96,345.EBI TBA
21366266 66 Discovery of a potent and efficacious peptide derivative ford/µ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.EBI University of Arizona
20178322 22 Discovery of dipeptides with high affinity to the specific binding site for substance P1-7.EBI Uppsala University
19762245 69 The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety.EBI University of Arizona
 14 3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitutionEBI TBA
 76 Use of CoMFA in validating the conformation used in designing 4-(1H-benzimidazole-2-carbonyl)piperidines with H1/NK1 receptor antagonist activityEBI TBA
 42 Synthesis and structure-activity relationships for a series of substituted pyrrolidine NK1/NK2 receptor antagonistsEBI TBA
 17 4,4-Diphenyl-7-perhydrothiapyrano[3,4-c]pyrrolone, a new series of substance P receptors antagonistsEBI TBA
 4 Perhydrothiopyranopyrroles derivatives : A novel series of potent and selective nonpeptide NK1 antagonists.EBI TBA
 13 Alternative strategies towards the identification of chemical lead compounds by rational designEBI TBA
 23 Methionine replacements in biologically active peptidesEBI TBA
 6 Application of the multipin peptide synthesis technique for peptide receptor binding studies: Substance P as A model systemEBI TBA
 1 A facile synthesis of the novel Neurokinin A antagonist SR 48968EBI TBA
 1 Synthesis of RP-67,580, a new potent nonpeptide substance P antagonistEBI TBA
18821747 45 The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.EBI University of Arizona
18067242 6 Conformational comparisons of a series of tachykinin peptide analogs.EBI Mississippi State University
10937720 24 Combined tachykinin receptor antagonist: synthesis and stereochemical structure-activity relationships of novel morpholine analogues.EBI Sankyo Co., Ltd.
8759639 33 Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P.EBI Hebrew University of Jerusalem
8576917 79 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.EBI Lilly Research Laboratories
7689652 6 Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N alpha-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists.EBI Fujisawa Pharmaceutical Co., Ltd.
7513763 92 Identification of L-tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor.EBI Merck, Sharp and Dohme Research Laboratories
7490729 62 Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonists.EBI Merck, Sharp and Dohme Research Laboratories
2433445 4 [pGlu6,Pro9]SP6-11, a selective agonist for the substance P P-receptor subtype.EBI TBA
2433443 9 Antagonists of substance P. Further modifications of substance P antagonists obtained by replacing either positions 7, 9 or 7, 8 and 11 of SP with D-amino acid residues.EBI TBA
1714957 12 Pseudopeptide analogues of substance P and leucine enkephalinamide containing the psi (CH2O) modification: synthesis and biological activity.EBI Hebrew University of Jerusalem
1694545 28 Potent and highly selective neurokinin antagonists.EBI Glaxo Group Research Ltd.
1373191 15 Synthesis and substance P antagonist activity of naphthimidazolium derivatives.EBI Rochester
17221184 55 Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.BDB Columbia University
12721338 61 N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic properties.BDB Pudue Pharma Discovery Research
12438541 27 SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.BDB Sanofi-Synthélabo Recherche
12431845 84 Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.BDB Lilly Research Laboratories
11750180 139 Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.BDB Lilly Research Laboratories
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories
8627566 53 In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.BDB Hoechst Marion Roussel
8012715 38 GR113808: a novel, selective antagonist with high affinity at the 5-HT4 receptor.BDB Glaxo Group Research Ltd.
7830490 21 SR 142801, the first potent non-peptide antagonist of the tachykinin NK3 receptor.BDB Sanofi Recherche
7562491 10 Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity.BDB ZENECA Pharmaceuticals
17516639 29 Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.BDB University of Arizona at Tucson
18266313 30 A Structure-Activity Relationship Study and Combinatorial Synthetic Approach of C-Terminal Modified Bifunctional Peptides That Are delta/mu Opioid Receptor Agonists and Neurokinin 1 Receptor Antagonists.BDB University of Arizona at Tucson